Abeprazan (hydrochloride)

Abeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases[1].

Product Specifications

CAS Number

[1902954-87-3]

Product Name Alternative

DWP14012 (hydrochloride) ; Fexuprazan (hydrochloride)

UNSPSC

12352005

Target

Proton Pump

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/abeprazan-hydrochloride.html

Purity

99.87

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

CNCC1=CN(S(=O)(C2=CC=CC(F)=C2)=O)C(C3=CC=C(F)C=C3F)=C1OC.[H]Cl

Molecular Formula

C19H18ClF3N2O3S

Molecular Weight

446.87

References & Citations

[1]Sunwoo J, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2018 Jul;48 (2) :206-218.